We investigated the relationship between endocan (a marker of systemic inflammation) and the development of coronary collateral circulation (CCC) as evaluated by coronary angiography in patients with chronic stable angina pectoris. A total of 90 patients (32 poor CCC and 58 good CCC) were included in this study. Endocan levels were determined using a commercially available sandwich enzyme-linked immunosorbent assay kit with high sensitivity and specificity for detection of human endocan. In multivariate logistic regression analysis, low endocan levels were independently associated with good CCC (P < .001). Moreover, low high-sensitivity C-reactive protein levels were also independently associated with good CCC (P ¼ .020). We found an optimal cutoff point for endocan of 1.7 ng/mL; it predicted the presence of good CCC with a sensitivity of 72.4% and specificity of 65.6% (P < .001). The results of the present study suggest that measurement of endocan level may help clinicians to predict the development of CCC in patients with stable coronary artery disease.
Introduction
The development of coronary collateral circulation (CCC) is an adaptive response to chronic myocardial ischemia that protects tissue from damage and infarction. 1 These vessels provide an alternative source of blood supply to the myocardium in patients with stenotic or occlusive coronary lesions. An increase in coronary collateral blood flow may reduce angina symptoms and cardiovascular events and preserve contractile function. 2 Patients with coronary stenosis or occlusion develop varying degrees of collateral formation, despite similar degrees of coronary obstruction. Although the severity of coronary stenosis, levels of inflammatory cells, and certain growth factors (eg, vascular endothelial growth factor and angiopoietin) were suggested as potential determinants of collateral development, the mechanisms responsible for the variability in responses are still unclear. [3] [4] [5] [6] Inflammation, a central factor for the initiation and progression of atherosclerosis may be implicated in the variability of the collateralization because a complex interaction exists between inflammation and new blood vessel formation. 7 Inflammation plays an important role at all stages of coronary artery disease (CAD).
Endocan is a 50-kDa proteoglycan synthesized and secreted by activated vascular endothelium. 8 It can be detected in the circulation and is an indicator of angiogenesis and endothelial cell activation. 9 Previous studies reported that endocan played a significant role in endothelial dysfunction, since it regulated cell adhesion in inflammatory disorders. [10] [11] [12] Endocan affects endothelial cells by facilitating the effects of vascular endothelial growth factor (VEGF) A on its receptor (VEGFR-2), triggering endothelial permeability. 13 Concomitant upregulation of adhesion molecules leads to the release of 2 powerful neutrophil and monocyte chemokines, interleukin 8 and monocyte chemoattractant protein 1.
14 In this way, endocan acts on components that provide the essential substrate for recruitment, adhesion, and migration of leukocytes across the activated vascular endothelium.
In the present study, we examined the relationship between endocan (a marker of systemic inflammation) and the development of CCC as evaluated by coronary angiography in patients with chronic stable angina pectoris.
Materials and Methods

Study Design
We analyzed clinical and angiographic data of the patients who had CCC due to stable angina pectoris between March 2014 and November 2016 at the Ankara Numune Educational and Research Hospital. All patients had total occlusion in at least 1 major epicardial coronary artery as seen on coronary angiography. Patients with acute/chronic infective or inflammatory disease, chronic kidney disease (serum creatinine >2.0mg/dL), previous history of coronary artery bypass grafting, acute coronary syndrome within the last 3 months, severe valvular heart disease, hepatic and hemolytic disorders, and malignancy were excluded. Cardiovascular risk factors were ascertained based on the medical records. Hypertension was considered in patients with repeated blood pressure measurements >140/90 mm Hg or current use of antihypertensive drugs. Diabetes mellitus was defined as fasting plasma glucose !126 mg/dL on multiple measurements or current use of antidiabetic medication. Transthoracic echocardiography was performed in all patients, and left ventricular ejection fraction was calculated using Simpson method. Our ethical committee approved the study protocol, and written consent was obtained from each patient.
Coronary Angiography and Coronary Collateral Scoring
Coronary angiography was performed using the Judkins technique. Coronary angiograms and also collateral grading were examined by 2 experienced interventional cardiologists who were blinded to the clinical characteristics and laboratory results of the patients. Development of CCC was graded according to the Cohen-Rentrop method: grade 0, no filling of any collateral vessels; grade 1, filling of side branches of the artery to be perfused by collateral vessels without visualization of epicardial segment; grade 2, partial filling of the epicardial artery by collateral vessels; and grade 3, complete filling of the epicardial artery by a collateral vessel. 15 Patients with grades 0 to 1 were classified as poor CCC and patients with grades 2 to 3 as good CCC. If the patient had >1 vessel with CCC, collateral grading was performed according to the vessel that had a collateral.
Measurements
Peripheral venous blood samples were obtained on their admission to the inpatient ward. An automated blood cell counter (Beckman Coulter analyzer; Beckman Coulter, Brea, California) was used for measuring a complete blood count. Blood biochemistry parameters that were measured were creatinine, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). High-sensitivity C-reactive protein (hsCRP) measurement was carried out using an automated analyzer (Beckman Coulter analyzer, Wuhan, China) using nephelometric measurement during or after the coronary angiography. Blood samples for endocan from the patients were collected into plain tubes, and serum was separated after centrifugation at 1500g for 10 minutes and stored at 80 C until analysis. Blood samples from calcium-EDTA tubes were analyzed in an autoanalyzer. Endocan levels were determined using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kit with high sensitivity and specificity for detection of human endocan (Bester, Wuhan, China). All serum samples were routinely analyzed by ELISA in duplicate, and the results were averaged. Preliminary data obtained in our laboratory showed that the intra-assay and interassay coefficients of variation for endocan were 4.5% and 4.9%, respectively. Logistic regression analysis was performed in order to identify dependent predictors of good CCC. Variables that had an unadjusted P < .15 in logistic regression analysis were identified as potential risk markers and included in the full model. We eliminated potential risk markers with likelihood ratio tests with reduced model using multivariate logistic regression analyses. A 2-sided P < .05 was considered significant with a 95% confidence interval (CI). The receiver-operating characteristic (ROC) curve was used to show the sensitivity and specificity of endocan levels and optimal cutoff value for predicting good CCC.
Statistical Analysis
Results
A total of 90 patients (32 poor CCC and 58 good CCC) were included. Clinical, laboratory, and angiographic characteristics of the groups are presented in Table 1 . Current smoker, HDL-C, hsCRP, red cell distribution width, and endocan levels were significantly associated with the good CCC group. As shown in Figure 1 , patients with good CCC had lower endocan levels compared to those with poor CCC. In multivariate logistic regression analysis, low endocan levels were independently associated with good CCC. Moreover, low hsCRP was also independently associated with good CCC (Table 2) .
Correlation analysis indicated that endocan levels showed a significant and positive correlation with hsCRP (P < .001; Figure 2 ). Exploration of the discriminatory capability of endocan level for presence of good CCC with ROC curve revealed that the area under the curve was 0.728 (95% CI: 0.626-0.830; P < .001). We found an optimal cutoff point for endocan level of <1.7 (ng/mL) using with the Youden index (J ¼ max [Sensitivity þ Specificity À 1]). It is predicted that the presence of good CCC with a sensitivity of 72.4% and specificity of 65.6% (Figure 3 ).
Discussion
We found a significant relationship between low endocan levels and the presence of good CCC and also a positive correlation between endocan levels and hsCRP. To the best of our knowledge, this is the first study that investigated endocan levels as a novel marker of inflammatory and endothelial dysfunction in patients in the good CCC group and compared the results to the poor CCC group.
The presence of good collateral circulation has beneficial effects on ventricular function, infarct size, and aneurysm formation. 16 A meta-analysis of 12 studies showed that patients with good collateralization have 36% reduced mortality risk compared to patients with low collateralization. Therapeutic promotion of collateral growth is a valuable treatment strategy in patients who cannot be revascularized by percutaneous coronary intervention or coronary artery bypass grafting. It is important to define the determinants of CCC development by further studying CCC and its mechanisms. The process of CCC formation included vasculogenesis, angiogenesis, and artery vessel formation. 3 Many factors affect the formation of CCC, such as the duration and/or severity of coronary artery stenosis, endothelial dysfunction, shear stress, endogenous mediators, hypertension, diabetes mellitus, dyslipidemia, smoking, and drugs. The endogenous mediators include vascular endothelial growth factor, transforming growth factor a or b, fibroblast growth factor, nitric oxide, inflammatory markers, and neurohumoral factors in angiogenesis. Moreover, the inflammatory cells, including monocytes, neutrophils, lymphocytes, and nature killer cells, secreted proinflammatory enzymes and cytokines that may play a role in the formation of CCC. 17, 18 Endocan is a soluble 50-kDa proteoglycan expressed by vascular endothelial cells, epithelial cells lining bronchi, renal tubules, and lung submucosal glands. [19] [20] [21] [22] Previous studies showed that endocan is overexpressed in several diseases such as sepsis, cancer, obesity, or inflammatory conditions. 23 Expression of endocan is regulated by a number of cytokines and growth factors. The lipopolysaccharide, tumor necrosis factor a (TNF-a), and interleukin 1 have been shown to induce endocan expression in vitro, while interferon gamma inhibits TNF-a-induced upregulation of endocan. 24 Endocan may play a key role in the vascular contribution to endothelium-dependent pathological disorders and may represent a novel endothelial dysfunction marker. 25 Balta et al have previously shown that patients with Behcet disease had significantly higher levels of endocan. Also, they have shown in patients with Behcet disease that endocan levels correlated positively with C-reactive protein, erythrocyte sedimentation rate, and disease activity. Endocan levels were also higher in patients with systemic involvement. 26 They have also previously shown that patients with psoriasis vulgaris had significantly higher levels of endocan. Additionally, in patients with psoriasis, endocan levels correlated positively with cardiovascular risk and activity of disease. 10 Scherpereel et al reported that in patients with sepsis, endocan levels are related to the severity of illness and the outcome of the patient and may represent a novel endothelial dysfunction. 25 Altintas et al reported that endocan levels correlated with obstructive sleep apnea severity and were significantly and independently correlated with carotid intima-media thickness. 27 Another study demonstrated that endocan levels are independently associated with the presence and severity of CAD in patients with hypertension. 28 Recently, we found that endocan levels are significantly and independently related to the presence of coronary slow flow, and endocan levels may be a useful predictor of inhospital mortality and coronary severity index in patients with ST-segment elevation myocardial infarction. 29, 30 According to these results, endocan levels, an endothelial dysfunction and inflammatory marker, may influence the pathogenesis of CCC. Therefore, we aimed to investigate a significant correlation between the presence of good CCC and endocan levels. Our findings revealed that endocan levels were significantly lower in the good CCC group compared to the poor CCC group. Also, we found an optimal cutoff point for endocan level of <1.7 (ng/mL); it predicted the presence of good CCC with a sensitivity of 72.4% and specificity of 65.6%. Endocan also had a positive correlation with serum hsCRP level that supports its role in systemic inflammation. Endocan, an indicator combining both inflammation and endothelial dysfunction, may gain a role in the prediction of CCC in daily clinical practice. Our results are in agreement with previous studies. Zorkun et al found that a high hsCRP level had a negative effect on coronary collateral development. 31 Gulec et al found that elevated hsCRP levels were associated with a significant impairment in coronary collateral development in patients with coronary stenosis. 32 Our study has several limitations. First, the sample size was relatively small, and we do not have any control group with normal coronary angiograms. A single measurement of endocan may not reflect lifetime status, and coronary collateralization progresses over many years. In this study, the patients had not undergone intravascular ultrasonography (IVUS) to measure coronary collateralization. The gold standard for measuring collateralization is intravascular hemodynamic assessment (coronary flow index). However, invasiveness of IVUS limits its use in large-scale studies. Also, the Rentrop scoring system was used for collateral grading although small microvascular caliber vessels may not be visualized angiographically.
In conclusion, the results of the present study suggest that measurement of endocan level may help clinicians for predicting the development of CCC in patients with stable CAD. Further larger studies are needed to confirm these results.
